Calithera Biosciences Price To Sales vs. Return On Asset

CALADelisted Stock  USD 0.05  0.00  0.00%   
Based on Calithera Biosciences' profitability indicators, Calithera Biosciences may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in December. Profitability indicators assess Calithera Biosciences' ability to earn profits and add value for shareholders.
For Calithera Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Calithera Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Calithera Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Calithera Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Calithera Biosciences over time as well as its relative position and ranking within its peers.
  
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
Please note, there is a significant difference between Calithera Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Calithera Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Calithera Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Calithera Biosciences Return On Asset vs. Price To Sales Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Calithera Biosciences's current stock value. Our valuation model uses many indicators to compare Calithera Biosciences value to that of its competitors to determine the firm's financial worth.
Calithera Biosciences is rated below average in price to sales category among its peers. It is rated below average in return on asset category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Calithera Biosciences by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Calithera Biosciences' Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Calithera Return On Asset vs. Price To Sales

Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.

Calithera Biosciences

P/S

 = 

MV Per Share

Revenue Per Share

 = 
1.71 X
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.

Calithera Biosciences

Return On Asset

 = 

Net Income

Total Assets

 = 
-0.56
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.

Calithera Return On Asset Comparison

Calithera Biosciences is currently under evaluation in return on asset category among its peers.

Calithera Biosciences Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Calithera Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Calithera Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of Calithera Biosciences' change in net profit over the period of time. It can combine multiple indicators of Calithera Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California. Calithera Biosci operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 63 people.

Calithera Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Calithera Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Calithera Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Calithera Biosciences' important profitability drivers and their relationship over time.

Use Calithera Biosciences in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Calithera Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Calithera Biosciences will appreciate offsetting losses from the drop in the long position's value.

Calithera Biosciences Pair Trading

Calithera Biosciences Pair Trading Analysis

The ability to find closely correlated positions to Calithera Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Calithera Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Calithera Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Calithera Biosciences to buy it.
The correlation of Calithera Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Calithera Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Calithera Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Calithera Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Calithera Biosciences position

In addition to having Calithera Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Monster Funds Thematic Idea Now

Monster Funds
Monster Funds Theme
Solid funds with above average long term performance indicators based on Macroaxis rating system. The Monster Funds theme has 50 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Monster Funds Theme or any other thematic opportunities.
View All  Next Launch
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.

Other Consideration for investing in Calithera Pink Sheet

If you are still planning to invest in Calithera Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Calithera Biosciences' history and understand the potential risks before investing.
Transaction History
View history of all your transactions and understand their impact on performance
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals